2008
DOI: 10.1503/cmaj.070874
|View full text |Cite
|
Sign up to set email alerts
|

The effect of vapocoolant spray on pain due to intravenous cannulation in children: a randomized controlled trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

3
78
0
3

Year Published

2008
2008
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 93 publications
(84 citation statements)
references
References 30 publications
(25 reference statements)
3
78
0
3
Order By: Relevance
“…Vapocoolant sprays have variably been reported to be ineffective (Costello et al, 2006 Level II) or reduce pain (Farion et al, 2008 Level II) associated with IV cannulation, and to be as effective as topical amethocaine in children undergoing venipuncture (Davies & Molloy, 2006 Level III-1).…”
Section: Venipuncture and Intravenous Cannulationmentioning
confidence: 99%
“…Vapocoolant sprays have variably been reported to be ineffective (Costello et al, 2006 Level II) or reduce pain (Farion et al, 2008 Level II) associated with IV cannulation, and to be as effective as topical amethocaine in children undergoing venipuncture (Davies & Molloy, 2006 Level III-1).…”
Section: Venipuncture and Intravenous Cannulationmentioning
confidence: 99%
“…Pain Ease Ò is a vapocoolant spray that acts in less than a minute; it contains 1,1,1,3,3-pentafluoropropane and 1,1,1,2-tetrafluoroethane and was shown in an RCT to reduce intravenous cannulation-related pain in children aged 6-12 years and to improve the success rate of cannulations [115]. Pain Ease Ò was preferred to ice applications prior to intravenous cannulations in children in one small study [116].…”
Section: Topical Anestheticsmentioning
confidence: 99%
“…However, the topical anesthetic wears off very quickly, but this should not be a problem since it can be reapplied as often as needed. A randomized controlled study in the pediatric emergency department at a Canadian Children's hospital documented a significant decrease in pain (mean difference 19 mm, 95 % CI 6-32 mm on NRS, p \ 0.01) with the use of the vapocoolant Pain-Ease compared to a placebo spray and a greater first attempt intravenous cannulation success rate (85 vs. 62.5 % for the placebo spray, 95 % CI 3.2-39.9 %, p = 0.03) with a number needed to treat to prevent 1 cannulation failure was 5 (95 % CI 3-32) [38]. The vapocoolants may be associated with minimal erythema or blanching of the skin in some patients which resolves in \5 min [37].…”
Section: Needle-free Injectablesmentioning
confidence: 99%